Recursion Pharmaceuticals (RXRX) Retained Earnings (2021 - 2026)

Recursion Pharmaceuticals has reported Retained Earnings for 6 years, with the latest figure at -$2.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 37.5% year-over-year to -$2.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.2 billion (down 37.5% YoY), and the FY2025 full-year result was $36.7 million, up 580.78% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.2 billion, down from $36.7 million in the prior quarter.
• The five-year high for Retained Earnings was $43.6 million in Q2 2025, with the low at -$2.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$860.3 million across 5 years, with a median of -$743.2 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings sank 29105100.0% — and 2025, when it surged 580.78%.
• Recursion Pharmaceuticals' Retained Earnings stood at -$639.6 million in 2022, then plunged by 36.75% to -$874.6 million in 2023, then jumped by 99.13% to -$7.6 million in 2024, then surged by 580.78% to $36.7 million in 2025, then plunged by 6091.77% to -$2.2 billion in 2026.
• The last three Retained Earnings figures came in at -$2.2 billion (Q1 2026), $36.7 million (Q4 2025), and -$2.0 billion (Q3 2025), per Business Quant data.